Literature DB >> 20940048

Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function.

Wai-Ping Fung-Leung1.   

Abstract

PI3Kδ is a lipid kinase of the PI3K class IA family involved in early signaling events of leukocytes responding to a wide variety of stimuli. The leukocyte specificity of PI3Kδ is defined by its expression, whereas its signaling function is via the production of phosphoinositide 3,4,5-triphosphates at the proximity of activated receptors for recruiting other signaling molecules. The importance of PI3Kδ in B cell development and function is most apparent, and its role in other leukocyte cell types can be easily demonstrated as well. PI3Kδ participates in the development, activation and migration of T cells and NK cells. The role of PI3Kδ in myeloid cell activities, such as inflammation driven cell infiltration, neutrophil oxidative burst, immune complex mediated macrophage activation, as well as mast cell maturation and degranulation, has been well illustrated in various studies. As a result of the broad effects of PI3Kδ in leukocyte functions, the disruption of PI3Kδ expression or activity leads to decreased inflammatory and immune responses in vivo. The protective role of PI3Kδ inactivation in animal models of arthritis, asthma or obstructive respiratory diseases has been demonstrated. These findings suggest the potential efficacy achievable with PI3Kδ inhibitors in the treatment of autoimmune and respiratory diseases.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20940048     DOI: 10.1016/j.cellsig.2010.10.002

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  37 in total

Review 1.  Phosphatidylinositol-3,4,5-triphosphate and cellular signaling: implications for obesity and diabetes.

Authors:  Prasenjit Manna; Sushil K Jain
Journal:  Cell Physiol Biochem       Date:  2015-02-11

2.  Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases.

Authors:  Montse Erra; Joan Taltavull; Angelique Gréco; Francisco Javier Bernal; Juan Francisco Caturla; Jordi Gràcia; María Domínguez; Mar Sabaté; Stéphane Paris; Salomé Soria; Begoña Hernández; Clara Armengol; Judit Cabedo; Mónica Bravo; Elena Calama; Montserrat Miralpeix; Martin D Lehner
Journal:  ACS Med Chem Lett       Date:  2016-11-30       Impact factor: 4.345

3.  The p110δ subunit of PI3K regulates bone marrow-derived eosinophil trafficking and airway eosinophilia in allergen-challenged mice.

Authors:  Bit Na Kang; Sung Gil Ha; Xiao Na Ge; M Reza Hosseinkhani; Nooshin S Bahaie; Yana Greenberg; Malcolm N Blumenthal; Kamal D Puri; Savita P Rao; P Sriramarao
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-03-16       Impact factor: 5.464

4.  β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity.

Authors:  Kinga Majchrzak; Michelle H Nelson; Jacob S Bowers; Stefanie R Bailey; Megan M Wyatt; John M Wrangle; Mark P Rubinstein; Juan C Varela; Zihai Li; Richard A Himes; Sherine Sl Chan; Chrystal M Paulos
Journal:  JCI Insight       Date:  2017-04-20

5.  Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.

Authors:  Susan O'Brien; Manish Patel; Brad S Kahl; Steven M Horwitz; Francine M Foss; Pierluigi Porcu; Jeffrey Jones; Jan Burger; Nitin Jain; Kerstin Allen; Kerrie Faia; Mark Douglas; Howard M Stern; Jennifer Sweeney; Patrick Kelly; Virginia Kelly; Ian Flinn
Journal:  Am J Hematol       Date:  2018-10-20       Impact factor: 10.047

6.  Inhibition of PI3Kδ improves systemic lupus in mice.

Authors:  Yanxia Wang; Lei Zhang; Ping Wei; Huailiang Zhang; Cuijie Liu
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

Review 7.  PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.

Authors:  Taemin Oh; Michael E Ivan; Matthew Z Sun; Michael Safaee; Shayan Fakurnejad; Aaron J Clark; Eli T Sayegh; Orin Bloch; Andrew T Parsa
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

8.  Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.

Authors:  Steven M Horwitz; Raphael Koch; Pierluigi Porcu; Yasuhiro Oki; Alison Moskowitz; Megan Perez; Patricia Myskowski; Adam Officer; Jacob D Jaffe; Sara N Morrow; Kerstin Allen; Mark Douglas; Howard Stern; Jennifer Sweeney; Patrick Kelly; Virginia Kelly; Jon C Aster; David Weaver; Francine M Foss; David M Weinstock
Journal:  Blood       Date:  2017-12-12       Impact factor: 22.113

Review 9.  PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.

Authors:  Rosalin Mishra; Hima Patel; Samar Alanazi; Mary Kate Kilroy; Joan T Garrett
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

10.  Phosphoinositide 3-Kinase Is Involved in Mediating the Anti-inflammation Effects of Vasopressin.

Authors:  Woan-Ching Jan; Ming-Chang Kao; Chen-Hsien Yang; Ya-Ying Chang; Chun-Jen Huang
Journal:  Inflammation       Date:  2017-04       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.